The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Foundation Medicine; GlaxoSmithKline; Lilly; Merck; Novartis
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Timothy Jay Price
Honoraria - SERVIER
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Merck
Research Funding - AMGEN (Inst)
Travel, Accommodations, Expenses - Amgen
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Inspirna (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Jean-Pierre Delord
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); MSD Oncology (Inst); Transgene (Inst)
 
Grace K. Dy
Consulting or Advisory Role - AstraZeneca; Lilly; Mirati Therapeutics
Research Funding - AMGEN (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Tesaro (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; GlaxoSmithKline; Lilly/ImClone; Merck; Mirati Therapeutics; Takeda
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - American Cancer Society
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Pionyr; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Exelixis (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Juergen Wolf
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma Europe; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo; Loxo/Lilly; MSD; Novartis; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
Adrian G. Sacher
Honoraria - Amgen; AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Genentech/Roche
Research Funding - AstraZeneca; Genentech/Roche
 
Alfredo Addeo
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Lilly
Travel, Accommodations, Expenses - Roche; Takeda
 
Hans Prenen
Honoraria - Amgen; Bayer; Roche; Sanofi
 
Antreas Hindoyan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Abraham Anderson
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on several Amgen patents. I do not receive royalties on these patents.
Travel, Accommodations, Expenses - Amgen
 
Agnes Ang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Ferdinandos Skoulidis
Stock and Other Ownership Interests - BioNTech; Moderna Therapeutics
Honoraria - ESMO; McGill Universite de Montreal; RV Mais
Consulting or Advisory Role - Amgen; BeiGene; Calithera Biosciences; Intellisphere; Medscape; Navire; Tango Therapeutics
Research Funding - AIMM Therapeutics (I); Amgen (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)